5-10-04



AK 1646

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Michael G. Walker

Title: ANKYRIN REPEAT DOMAIN 2 PROTEIN VARIANT

Serial No.: 09/758,593 Filing Date: January 10, 2001

Group Art Unit: 1646


Commissioner for Patents USPTO P.O. Box 1450 Alexandria, VA 22313-1450

## CERTIFICATE UNDER 37 C.F.R. § 3.73(b), REVOCATION OF POWER OF ATTORNEY AND APPOINTMENT OF NEW ATTORNEYS

Sir:

The undersigned has reviewed all the documents in the chain of title of the aboveidentified patent application and, to the best of undersigned's knowledge and belief, title is in the assignee identified below.

Incyte Corporation, formerly known as Incyte Genomics, Inc., also formerly known as Incyte Pharmaceuticals, Inc., having a principal place of business located at 3160 Porter Drive, Palo Alto, California 94304, certifies that it is the assignee and owner of the entire right, title and interest in, to, and under the invention described and claimed in the above-identified application by virtue of an Assignment recorded at Reel 011909, Frame 0532, hereby revokes all previous powers of attorney and appoints those practitioners under Customer No. 22428 as attorneys/ agents with full power of substitution to prosecute this application and to transact all business in the Patent and Trademark Office in connection therewith.



Michele M. Simkin, Esq. Reg. No. 34,717 Customer No.: 22428 Foley & Lardner LLP Washington Harbour 3000 K Street, N.W., Suite 500 Washington, D.C. 20007-5109

and direct all telephone calls and facsimile transmissions to: Foley & Lardner LLP; Phone:Tel: (202) 672-5300 Fax: (202) 672-5399 The undersigned (whose title is supplied below) is empowered to act on behalf of the assignee.

I hereby declare that all statements made herein are of my own knowledge are true and that all statements made on information and belief are believed to be true, and further that these statements are made with the knowledge that willful false statements and the like so made are punishable by fine of imprisonment, or both, under Section 1001, Title 18, of the United States Code, and that such willful false statements may jeopardize the validity of the patent.

INCYTE CORPORATION

Date: Cipul 28 2004

ĭ

Patricia Anne Schreck

Executive VP, General Counsel